The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis
Open accessAbstract
Learning Objectives: Describe the influences of different types of glucose-lowering medications on therapeutic outcomes of cancer patients who received standard anticancer treatment. Compare the survival associated with metformin treatment with survival in treatment with other glucose-lowering medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In human cancer patients with diabetes, metformin was associated with a decrease in 2-year mortality compared with other glucose-lowering medications (88).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Adjusting for publication bias in the presence of heterogeneity
Terrin, N., Schmid, C. H., Lau, J., & Olkin, I. (2003) · Statistics in Medicine · doi:10.1002/sim.1461 · Cited by 809
Research works printed but not linked: 1
- Sandulache, 2013, Metformin use is associated with improved survival in patients with laryngeal squamous cell carcinoma, Head Neck
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Palmer, A. K., Tchkonia, T., LeBrasseur, N. K., Chini, E. N., Xu, M., & Kirkland, J. L. (2015) · Diabetes · doi:10.2337/db14-1820 · Cited by 423
Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
Slomovitz, B. M., Jiang, Y., Yates, M. S., Soliman, P. T., Johnston, T., Nowakowski, M., Levenback, C., Zhang, Q., Ring, K., Munsell, M. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3401 · Cited by 324
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Metadata
- Authors
- Yin, M., Zhou, J., Gorak, E. J., & Quddus, F.
- Affiliations
- Department of Internal Medicine, Danville, Pennsylvania, USA
- Geisinger Medical Center (US)
- Corresponding author
- Yin, Ming
- Quddus, Fahd
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-20
- Volume
- 18
- Issue
- 12
- Pages
- 1248-1255
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC3868417
- OpenAlex
- W2146511561
- Cited by
- 157
- References
- 55
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 9 · 2021: 15 · 2020: 16 · 2019: 7 · 2018: 11 · 2017: 13 · 2016: 22 · 2015: 22 · 2014: 16 · 2013: 1
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- metformin, type 2 diabetes, cancer, overall survival, cancer-specific survival, glucose-lowering medications, cancer mortality, drug repurposing
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1634/theoncologist.2013-0111
- The paper
- Yin, M., Zhou, J., Gorak, E. J., & Quddus, F. (2013). Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis. The Oncologist. https://doi.org/10.1634/theoncologist.2013-0111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.